A Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Quality

Basit Öğe Kaydı
dc.WoS.categoriesMedicine, General & Internalen_US
dc.authorid0000-0002-6180-2969en_US
dc.contributor.authorAkgün, Züleyha
dc.contributor.authorÇakır, Aydın
dc.contributor.authorSağlam, Esra
dc.contributor.authorDemirel, Sertaç
dc.contributor.authorIğcı, Abdullah
dc.contributor.authorKeskin, Serkan
dc.date.accessioned2023-09-19T07:23:47Z
dc.date.available2023-09-19T07:23:47Z
dc.date.issued2023-04
dc.description.abstractIntroduction: This study aimed to evaluate the long-term adverse effects on the physical appearance and overall well-being of breast cancer patients who receive hypofractionated radiotherapy as whole breast and simultaneous integrated boost (SIB) treatment, utilizing intensive modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), or a hybrid therapy approach. Material/Methods: This investigation involved administering hypofractionated SIB-VMAT therapy to individuals diagnosed with early-stage breast cancer. Treatment was carried out over a three-week period in which a total dose of 48.06 Gy was given to the entire breast and 54 Gy was given to the tumor bed. Data on skin toxicity and cosmetic outcomes were analyzed both during the acute phase and during the three-month and five-year follow-up periods after treatment. Results: A total of 125 patients treated between December 2014 and December 2016 were included in the study. The data of these patients with at least 5 years of follow-up were analyzed. Conclusions: Considering these long-term results, hypofractionated SIB-VMAT can be considered a viable treatment choice, even for patients with unfavorable conditions.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.3390/medicina59040675en_US
dc.identifier.issn1648-9144
dc.identifier.issn1010-660X
dc.identifier.pmid37109633en_US
dc.identifier.scopus2-s2.0-85156136123en_US
dc.identifier.urihttps://hdl.handle.net/11411/5195
dc.identifier.urihttps://doi.org/10.3390/medicina59040675
dc.identifier.wosWOS:000977548700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.issue4en_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors6en_US
dc.publisherMDPIen_US
dc.relation.ispartofMEDICINA-LITHUANIAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbreast canceren_US
dc.subjectSIBen_US
dc.subjecthypofractionationen_US
dc.subjecthybrid radiotherapyen_US
dc.subjectlate toxicityen_US
dc.titleA Hypofractionated Radiotherapy Schedule with a Simultaneous Integrated Boost for Breast Cancer: Outcomes including Late Toxicity and Health Qualityen_US
dc.typeArticleen_US
dc.volume59en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2023WosÇakır.pdf
Boyut:
292.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
Web of Science Indexed Publications